SUMMARY
Tumor necrosis factor-stimulated gene-6 (TSG-6), an anti-inflammatory protein, was shown to be localized in the neointima of injury-induced rat arteries. However, the modulatory effect of TSG-6 on atherogenesis has not yet been reported. We aimed to evaluate the atheroprotective effects of TSG-6 on human endothelial cells (HECs), human monocyte-derived macrophages (HMDMs), human aortic smooth muscle cells (HASMCs) in vitro, and aortic lesions in apolipoprotein E-deficient mice, along with expression levels of TSG-6 in coronary lesions and plasma from patients with coronary artery disease (CAD). TSG-6 was abundantly expressed in HECs, HMDMs, and HASMCs in vitro. TSG-6 significantly suppressed cell proliferation and lipopolysaccharide-induced up-regulation of monocyte chemotactic protein-1, intercellular adhesion molecule-1, and vascular adhesion molecule-1 in HECs. TSG-6 significantly suppressed inflammatory M1 phenotype and suppressed oxidized low-density lipoprotein-induced foam cell formation associated with down-regulation of CD36 and acyl-CoA:cholesterol acyltransferase-1 in HMDMs. In HASMCs, TSG-6 significantly suppressed migration and proliferation, but increased collagen-1 and -3 expressions. Four-week infusion of TSG-6
into apolipoprotein E-deficient mice significantly retarded the development of aortic atherosclerotic lesions with decreased vascular inflammation, monocyte/macrophage, and SMC contents and increased collagen fibers. In addition, it decreased peritoneal M1 macrophages with down-regulation of inflammatory molecules and lowered plasma total cholesterol levels. In patients with CAD, plasma TSG-6 levels were significantly increased, and TSG-6 was highly expressed in the fibrous cap within coronary atherosclerotic plaques. These results suggest that contributes to the prevention and stability of atherosclerotic plaques. Thus, TSG-6 may serve as a novel therapeutic (1, (5) (6) (7) . TSG-6 inhibits leukocyte adhesion onto the vascular wall and leukocyte migration (8, 9) . In addition, TSG-6 down-regulates toll-like receptor-2/ nuclear factor (NF)-kB and up-regulates cyclooxygenase (COX)-2 in mouse macrophages (10, 11) . Although TSC-6 was shown to be localized in rat neointima after arterial injury and rabbit carotid atherosclerotic plaques (12, 13) , there have been no previous reports regarding its direct effect on atherogenesis.
Atherosclerosis is a chronic inflammatory response to arterial wall injuries (14) . Endothelial inflammation stimulates the production of proin- 
Watanabe et al. were added to each well (19, 22, 23) . After 1 h of incubation, the amount of formazan product was determined by measuring the absorbance at 450 nm using a Sunrise Remote R-microplate reader (Tecan, Kawasaki, Japan) (19, 22, 23) . ZYMOGRAPHY. The activities of MMP-2 and -9 were determined using a gelatin zymography kit (Cosmo Bio, Tokyo, Japan) (23) . The culture supernatants of HASMCs (15 mg) were mixed with 5 ml of sample buffer and fractionated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis using 0.1% gelatin. After electrophoresis, the gel was washed with renaturing buffer (2% Triton X-100) for 1 h.
The gel was incubated for 20 h at 37 C in a reaction buffer (1% Triton X-100) and then was stained with
Coomassie brilliant blue (23) . purchased from Japan SLC Inc. (Hamamatsu, Japan) and maintained on a normal diet until they reached the age of 13 weeks. Then, a high-cholesterol diet (Oriental Yeast, Tokyo, Japan) was started (19, 22, 23) .
Two groups of 17-week-old ApoE À/À mice were infused with saline (vehicle) or TSG-6 (75 ng/kg/min) (GenWay Biotech, San Diego, California) for 4 weeks using osmotic mini-pumps (Alzet Model 1002, Durect, Cupertino, California) (19, 22) . The doses of TSG-6
were decided on the basis of our preliminary examinations and a previous report (26) .
Systolic and diastolic blood pressures were measured using the indirect tail-cuff method (Kent Scientific, Torrington, Connecticut). Four days before the endpoint of infusion, mice were intraperitoneally injected with 2 ml of aged-autoclaved thioglycolate broth to obtain exudate peritoneal macrophages, which is thought to mimic arterial macrophages present in atheroma areas (22, 27) . Exudate peritoneal macrophages are widely accepted to use in the assessment of mouse atherosclerosis (22, 27) .
At the experimental endpoint (before and 4 weeks after infusion), the ApoE À/À mice were sacrificed by exsanguination (total blood collection) under deep ether anesthesia (19, (21) (22) (23) 
RESULTS

EXPRESSION OF TSG-6 IN HUMAN VASCULAR CELLS IN
VITRO. TSG-6 was expressed at infinitesimal levels in human monocytes but at high levels in HMDMs, HASMCs, and HUVECs ( Figure 1A) . The independent experiment that was repeated once more also confirmed the same results. The results were consistent with the previous reports (1,5-7) .
EFFECTS OF TSG-6 ON PROLIFERATION AND INFLAMMATORY RESPONSE IN HUMAN ECs. In a normal glucose condition (1.0 mg/ml), TSG-6 at 5 to 300 ng/ml significantly suppressed the proliferation of EA.hy926 ECs, with the maximal reduction by w10% ( Figure 1B) . In a high glucose condition (4.5 mg/ml), TSG-6 significantly suppressed the proliferation only at 300 ng/ml, with a maximal reduction of w25% ( Figure 1B) . The micrographs confirmed that the reduction in cell number was not attributed to death due to apoptosis and cytotoxicity by 4.5 mg/ml glucose and/or 300 ng/ml TSG-6 ( Figure 1B (Figure 2A ). TSG-6 did not affect monocyte differentiation into HMDMs. However, TSG-6 significantly decreased the expression of MARCO, an M1 marker, on day 6 and showed a tendency to increase the expression of MRC1, an M2 marker, only on day 3 but not on day 6. These observations indicated that TSG-6 shifted the macrophage phenotype overwhelmingly to M2 rather than M1.
As shown in Figure 2B , TSG-6 showed a tendency to suppress IL-6 secretion and significantly suppressed TNF-a secretion from HMDMs. However, TSG-6 did not significantly suppress the LPS-induced IL-6 and TNF-a secretion from HMDMs (Supplemental Figure 1) .
EFFECTS OF TSG-6 ON FOAM CELL FORMATION IN
HMDMs. TSG-6 significantly suppressed oxLDLinduced foam cell formation by 25% at 50 ng/ml in HMDMs ( Figure 2C) . In HMDMs just before oxLDL was added, TSG-6 significantly suppressed CD36 and ACAT1 protein expression ( Figures 2D and 2E ) and showed a tendency to increase ABCA1 protein expression ( Figure 2F (B) HMDMs differentiated by 10% human serum without TSG-6 were incubated for 26 h in serum-free RPMI-1640 medium with or without TSG-6 (300 ng/ml). The concentrations of IL-6 and TNF-a in culture supernatants were measured by enzyme-linked immunosorbent assay.
Baseline of control ¼ 27.3 AE 11.9 pg/ml (IL-6) and 34.7 AE 3.1 pg/ml (TNF-a). n ¼ 3; †p ¼ 0.028 vs. control. (C) Human monocytes were incubated to differentiate into HMDMs for 7 days in RPMI-1640 with 10% human serum and the indicated concentrations of TSG-6, followed by a further 19 h with the same concentrations of TSG-6, 50 mg/ml oxLDL, and 0.1 mmol/l [ 
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31% at 300 ng/ml ( Figure 3A) . The reduction in cell number was not attributed to death due to apoptosis and cytotoxicity by 300 ng/ml TSG-6 ( Figure 3A) . In addition, the migration of HASMCs was significantly increased by the treatment with 500 nmol/l AngII ( Figure 3B) . However, TSG-6 significantly suppressed the AngII-induced migration of HASMCs ( Figure 3B) . HASMCs was determined in 10 cells/well using a BIOREVO BZ-9000 microscope in serum-free medium with or without AngII (500 nmol/l) and/or TSG-6 (300 ng/ml). n ¼ 30 from 3 independent experiments. #p < 0.0001. (C) To assess their signal transductions, HASMCs that were incubated for 48 h with or without TSG-6 (300 ng/ml) were subjected to immunoblotting analysis for PI3K, c-Src, Raf-1, phosphorylated ERK1/2, JNK, and NF-kB. a-tubulin served as a loading control. n ¼ 3 to 4; §p ¼ 0.035; ¶p ¼ 0.020; ＠p ¼ 0.013 vs. 0 ng/ml of TSG-6.
All values are presented as mean AE SEM. AngII ¼ angiotensin II; NF-kB ¼ nuclear factor-kB; p-ERK ¼ phosphorylated ERK; PI3K ¼ phosphoinositide 3-kinase; VSMC ¼ vascular smooth muscle cell; other abbreviations as in Figure 1 . significantly developed by 2-fold ( Figures 5A, 5B, 5D , 5E, 5S, and 5T), whereas body weight significantly increased by 15% ( Table 2 ). At 21 weeks of age, TSG-6 levels in plasma were significantly increased by 1.6-fold in TSG-6-infused mice compared with their saline-infused counterparts ( Table 2 ). Chronic VSMC ¼ vascular smooth muscle cell; other abbreviations as in Figure 1 .
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infusion of TSG-6 significantly retarded the surface areas of the atherosclerotic lesions by 30%
( Figures 5B, 5C , and 5S), with little reduction of plaque size in the sinus ( Figures 5E, 5F , and 5T). In the atherosclerotic plaque, there was a significant reduction of monocyte/macrophage infiltration ( Figures 5H, 5I , and 5U). TSG-6 was prone to decreasing vascular inflammation ( Figures 5K, 5L , and 5V) and VSMC contents ( Figures 5N, 5O , and 5W) along with increasing collagen fibers ( Figures 5Q, 5R , and 5X).
Chronic infusion of TSG-6 significantly decreased cell number ( Table 2) , and protein expression of MARCO (M1 marker), MCP-1, COX-2, NF-kB, and phosphorylated ERK1/2, but not arginase-1 (M2 marker) in peritoneal exudate macrophages ( Figure 6 ). TSG-6 also showed a tendency to decrease pentraxin-3 and JNK expression ( Figure 6 ). As There were no significant differences in body weight, systolic and diastolic blood pressures, or plasma levels of glucose and pentraxin-3 between the 2 groups of ApoE À/À mice at 21 weeks of age ( Table 2 ). However, TSG-6 significantly decreased plasma total cholesterol levels and showed a tendency to increase HDL cholesterol levels.
PRESENCE OF TSG-6 IN HUMAN CORONARY ARTERY
LESIONS AND PLASMA. The levels of TSG-6 expression were assessed in human coronary arteries from 4 patients without CAD and 13 with CAD. Expression of TSG-6 was minimal in normal and nonstenotic coronary arteries from a patient without CAD and a patient with CAD, respectively ( Figures 7A to 7D ). In the stenotic coronary artery from another patient with CAD, TSG-6 was highly expressed in the fibrous cap within atherosclerotic plaques ( Figures 7E and 7F ), which were indicated by consistent areas stained blue with Masson's Trichrome ( Figure 7H ). The remaining patients with and without CAD showed similar results. Peritoneal cells obtained from ApoE À/À mice were suspended in conditioned medium and seeded onto 6-cm dishes (4 Â 10 6 cells per 2 ml/dish). After incubation for 1 h at 37 C in 5% CO 2 to allow adhesion, the medium was discarded to remove nonadherent cells. Immediately, adherent macrophages were harvested after washing the dishes with phosphate-buffered saline twice for immunoblotting analyses of MARCO (M1 marker), arginase-1 (M2 marker), MCP-1, pentratin-3, COX-2, NF-kB, JNK, and phosphorylated ERK1/2. b-actin served as a loading control. Abbreviations as in Figures 3 and 5 .
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Next, plasma TSG-6 levels were compared between 47 patients without CAD and 135 patients with CAD. As listed in Table 3 , age; prevalence of smoking, diabetes, and hypertension; and use of antidiabetic drugs were significantly greater and HDL cholesterol levels were significantly lower in patients with CAD than in subjects without CAD.
The prevalence of several kinds of antihypertensive and antidyslipidemia drugs, and LDL cholesterol levels did not differ significantly between the 2 groups. As shown in Figure 8 , plasma TSG-6 levels were significantly higher in patients with CAD than in subjects without CAD. Because a previous report showed increased TSG-6 levels in the airway secretions of smokers (28), we evaluated the relationship between plasma TSG-6 levels and smoking in patients without and with CAD. Representative normal coronary arteries (A and B) from a patient with dilated cardiomyopathy (male, age 34 years) and nonstenotic coronary arteries (C and D) from a patient with previous myocardial infarction (male, age 78 years), and representative stenotic coronary arteries (E to I) from a patient with previous myocardial infarction (male, age 62 years) were stained with anti-TSG-6 antibody (A to F); anti-a-SMA antibody, a VSMC marker (G); Masson's Trichrome, a collagen fiber marker (H); and anti-CD68 antibody, a macrophage marker (I). These patients died of heart failure or stroke. All coronary arteries were not the culprit artery of acute coronary events. CAD ¼ coronary artery disease; other abbreviations as in Figure 5 . The present results concerning the effect of TSG-6 on VSMC proliferation are inconsistent with a previous report. Ye et al. (12) showed that both rabbit aortic VSMCs and rat pulmonary VSMCs with overexpressing TSG-6 exhibited an increase in cell number in the serum-free culture system (12). In our We discuss the integrity of TSG-6 concentrations in our in vitro and in vivo experiments. First, the concentrations of TSG-6 required to modulate several responses of HMDMs, human ECs, and HASMCs were considerably high: 10-to 60-fold higher than plasma TSG-6 levels in humans (w5 ng/ml). In the vascular wall, large amounts of TSG-6 are mainly generated by vascular cells other than fibroblasts in an autocrine/ paracrine manner. Animal and clinical studies showed that local levels of other vasoactive agents such as serotonin and AngII were increased by 10-to 100-fold with coronary events in obstructive arteries and cardiac interstitial fluid (39, 40) , which is comparable with the present study. Second, the TSG-6 level in human serum from a healthy volunteer was 7.4 ng/ml in the present study. Therefore, the 10% concentration added to the culture medium for 
DISCUSSION
